| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 22.823 | 0 | 0 | - | - | - | - | - | - | - |
| Total Income - EUR | 23.314 | 0 | 0 | - | - | - | - | - | - | - |
| Total Expenses - EUR | 21.484 | 74 | 0 | - | - | - | - | - | - | - |
| Gross Profit/Loss - EUR | 1.830 | -74 | 0 | - | - | - | - | - | - | - |
| Net Profit/Loss - EUR | 1.830 | -74 | 0 | - | - | - | - | - | - | - |
| Employees | 0 | 0 | 0 | - | - | - | - | - | - | - |
Check the financial reports for the company - Synthesis Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.405 | 2.380 | 2.340 | - | - | - | - | - | - | - |
| Current Assets | 165.470 | 162.791 | 160.036 | - | - | - | - | - | - | - |
| Inventories | 42.779 | 42.342 | 41.626 | - | - | - | - | - | - | - |
| Receivables | 121.702 | 120.450 | 118.412 | - | - | - | - | - | - | - |
| Cash | 989 | -2 | -2 | - | - | - | - | - | - | - |
| Shareholders Funds | -546.407 | -540.908 | -531.755 | - | - | - | - | - | - | - |
| Social Capital | 135 | 134 | 131 | - | - | - | - | - | - | - |
| Debts | 750.209 | 741.640 | 729.090 | - | - | - | - | - | - | - |
| Income in Advance | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Synthesis Pharma S.r.l.